Drug Trial Radar · NCT03940352
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
52
Actual
Start
Jun 24, 2019
Primary completion
Aug 20, 2024
Study completion Aug 20, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status had to be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8. Two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2). * In the treatment arm 1, subjects received HDM201 in combination with MBG453. * In the treatment arm 2, subjects received HDM201 in combination with venetoclax. Venetoclax dose was gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that was subsequently continued. Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects was planned to be determined for each treatment arm.
Conditions
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
Interventions
HDM201Drug
Capsule
MBG453Biological
LIVI (Liquid in vial) Concentrate for Solution for infusion
VenetoclaxDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: at month 24
- Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safetyTime frame: at month 24
- Incidence of dose limiting toxicities (DLTs) of treatmentTime frame: at day 28
- Frequency of dose interuptionsTime frame: at month 24
- Frequency of dose reductionsTime frame: at month 24
- Dose intensitiesTime frame: at month 24
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Duke University Medical Center .
Durham, North Carolina
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.